Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06959277 · ClinicalTrials.gov registry record · NA

Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

A NA study of Peripheral Neuropathy Due to Chemotherapy and Peripheral Neuropathies, sponsored by RxFunction.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
6
Study locations

NCT06959277: Recruiting NA study of Peripheral Neuropathy Due to Chemotherapy and Peripheral Neuropathies, sponsored by RxFunction.

NCT06959277 is a NA study of Peripheral Neuropathy Due to Chemotherapy and Peripheral Neuropathies that is actively recruiting participants, run by RxFunction. The registered enrollment target is 200 participants, above the 28-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (614% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06959277, a NA study of Peripheral Neuropathy Due to Chemotherapy and Peripheral Neuropathies, is actively recruiting participants, sponsored by RxFunction.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of their foot placement on the ground. Researchers will compare Walkasins users to a control group of participants who are not using Walkasins to see if the device improves the users' performance on some standing and walking tests. Control group participants will get Walkasins after six months of being in the study. During the study participants will be asked to do the following: * Answer questions about their medical history and balance. * Do some standing and walking tests. Some of the tests will be timed. * Attend study visits and participate in study phone calls. * Keep track of any falls and notify study staff if they fall. * Wear the Walkasins device on a regular basis.

Primary Outcome

The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability.

Interventions

  • DEVICE Walkasins
  • OTHER Fall Prevention Training

Study Locations (6)

Arizona

  • OrthoArizona--Mesa Arbor Avenue - Mesa

Massachusetts

  • Marcus Institute for Aging Research, Hebrew SeniorLife - Boston

Minnesota

  • Fairview Frontiers - Saint Paul

New York

  • Dent Neurologic Institute - Amherst

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-06-17
Est. Completion 2027-12-31
Phase NA
RxFunction

5 total trials

What NCT06959277 shows while recruiting

NCT06959277 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 28-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (614% higher).

The record links to 5 conditions, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 2 interventions - of which Walkasins is the first listed.

NCT06959277 lists 6 locations in 6 states (Arizona, Massachusetts, Minnesota).

Frequently Asked Questions

What is clinical trial NCT06959277 about?

NCT06959277 is a clinical study titled "Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems". The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of thei...

What is the current status of trial NCT06959277?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-06-17. Estimated completion is 2027-12-31.

What conditions does trial NCT06959277 study?

This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathies, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly, Gait Disorders.

What interventions are being tested in trial NCT06959277?

The interventions under investigation include: Walkasins (DEVICE), Fall Prevention Training (OTHER).

Who is sponsoring clinical trial NCT06959277?

This trial is sponsored by RxFunction, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06959277 being conducted?

This trial has 6 study locations across Arizona, Massachusetts, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Neuropathy Due to Chemotherapy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06959277, the US trial registry maintained by the National Library of Medicine. NCT06959277 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.